« Return to News | R&D Trends | Drug Sponsors

ViroPharma contracts Recipharm to manufacture Plenadren

Monday, March 19, 2012 09:56 AM

Recipharm, the international contract pharmaceutical development and manufacturing organization, has been contracted by ViroPharma to complete commercial scale-up manufacture of Plenadren (hydrocortisone), used for the treatment of adrenal insufficiency in adults.

In addition, ViroPharma is investing in new equipment for Recipharm to increase the manufacturing capacity for Plenadren to support commercial product launches across Europe.

The new agreement follows the completion of Recipharm’s initial scale-up contract with DuoCort Pharma—recently acquired by ViroPharma following Plenadren’s receipt of European marketing authorization and confirmation of orphan drug designation.

Additionally, Recipharm will be able to use the new equipment for other projects, with ViroPharma retaining its status as highest priority customer.

Helene Fehrm, general manager of Recipharm Stockholm, said, “This investment and the work we are doing for ViroPharma will give us further valuable experience in tablet manufacturing with API in the coating—a unique advantage over conventional approaches—both for Plenadren itself and other customers moving forwards.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.